Business
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
WESTLAKE VILLAGE, Calif., May 11, 2026--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic conditions, today reported financial results for the three months ended March 31, 2026, and provided corporate updates.
About this update from Turn Therapeutics Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1911,"height":772,"url":"https://media.zenfs.com/en/business-wire.com/948fab1f252aa96a284935fe4551eea7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BpjiA_H5KyFuXCQrEFbB2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4OA--/https://media.zenfs.com/en/business-wire.com/948fab1f252aa96a284935fe4551eea7","width":960,"height":388},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/AH8gd3z4MfZ1DMPUsrY6zg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI1OQ--/https://media.zenfs.com/en/business-wire.com/948fab1f252aa96a284935fe4551eea7","width":640,"height":259},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/XH7TYzFYup5B3Z2ORQTLrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NzA-/https://media.zenfs.com/en/business-wire.com/948fab1f252aa96a284935fe4551eea7","width":1200,"height":485}},"lazy":false},{"type":"text","content":"Phase 2 Trial for GX-03 in Moderate-to-Severe Atopic Dermatitis (AD) on Track, Topline Results Expected Mid-2026","length":112,"tagName":"p","attribs":{}},{"type":"text","content":"Initial Tranche of $7 Million in Growth Capital has been Funded by Avenue Capital Group","length":87,"tagName":"p","attribs":{}},{"type":"text","content":"WESTLAKE VILLAGE, Calif., May 11, 2026--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic conditions, today reported financial results for the three months ended March 31, 2026, and provided corporate updates.","length":332,"tagName":"p"},{"type":"text","content":""The first quarter of 2026 materially strengthened Turn Therapeutics both operationally and financially," said Bradley Burnam, Chief Executive Officer of Turn Therapeutics. "With the Avenue Capital facility now in place, we believe the Company is well positioned to advance our clinical programs through multiple near-term catalysts while maintaining focus on disciplined execution. Our Phase 2 trial evaluating GX-03 in moderate-to-severe atopic dermatitis remains on schedule, with an independent committee expected to assess conditional probability of success at the interim analysis and determine whether the study should continue as designed or expand enrollment based on the s...